Priority Review Voucher Crash: Spark's Sale To Jazz Lowest Price Since 2014

Only the first publicly disclosed sale of a priority review voucher was lower than what Jazz Pharmaceuticals paid Spark Therapeutics for its coupon.

Priority Review Voucher

A growing supply appears to be forcing priority review voucher values down further, as the latest sale was the lowest since the first price was disclosed four years ago.

Spark Therapeutics Inc. announced April 30 that it will sell its priority review voucher to Jazz Pharmaceuticals PLC...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Rare Diseases

More from Pink Sheet